Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA).
A. Oliver Sartor
Consultant or Advisory Role - Algeta; Bayer
Honoraria - Algeta; Bayer
Daniel Heinrich
Consultant or Advisory Role - Algeta
Joe M. O'Sullivan
No relevant relationships to disclose
Sophie D. Fossa
No relevant relationships to disclose
Ales Chodacki
No relevant relationships to disclose
Pawel J. Wiechno
No relevant relationships to disclose
John P. Logue
No relevant relationships to disclose
Mihalj Seke
No relevant relationships to disclose
Anders Widmark
Employment or Leadership Position - Sanofi
Dag Clement Johannessen
No relevant relationships to disclose
Sten Nilsson
Consultant or Advisory Role - Algeta
Honoraria - Algeta
Peter Hoskin
No relevant relationships to disclose
David Bottomley
No relevant relationships to disclose
Robert Edward Coleman
Consultant or Advisory Role - Novartis
Honoraria - Amgen; Novartis
Expert Testimony - Novartis
Nicholas J. Vogelzang
Employment or Leadership Position - US Oncology
Consultant or Advisory Role - Algeta; Bayer
Honoraria - Johnson & Johnson
C. Gillies O'Bryan-Tear
Employment or Leadership Position - Algeta
Stock Ownership - Algeta
Jose E. Garcia-Vargas
Employment or Leadership Position - Bayer
Minghua Shan
Employment or Leadership Position - Bayer
Chris Parker
Consultant or Advisory Role - Algeta (U)
Honoraria - Bayer